Med-Chemist

Med-Chemist : "Quintessential Medicinal Chemistry"

Showing posts with label refractory mantle cell lymphoma. Show all posts
Showing posts with label refractory mantle cell lymphoma. Show all posts
Friday, March 1, 2024

FDA Approves Jaypirca (pirtobrutinib) for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma

›
Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY),  announced the U.S. Food and Drug Administration (FDA) approved  Jaypirc...
Monday, February 22, 2016

Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma

›
In continuation of my update on  Ibrutinib and  Temsirolimus Temsirolimus Phase III trial findings suggest that patients with relap...
›
Home
View web version

Contributors

  • Dr. Umesh..
  • https://www.med-chemist.com
Powered by Blogger.